OncoSil™ (originally called BrachySil™) is a 32P-loaded microparticle developed for the treatment of pancreatic cancer. In April 2020, OncoSil obtained European CE marking approval as a Brachytherapy device to treat locally advanced pancreatic cancer in combination with chemotherapy, clearing the way for marketing in both the EU and the U.K.
Target/Mechanism: Brachytherapy
Carrier/Ligand: n/a
Radiation Type: beta electrons (β–)
